Cribriform morphology in intermediate grade prostate cancer is defined by molecularly distinct subtypes
PCF 2026
Kerry R. Schaffer, Monika Antunovic, Xin Sun, Hong Yuen Wong, Amanda B. Hesterberg, Evan Watkins, Quanhu Sheng, Marisol Ramirez-Solano, Aaron Lee, Tatsuki Koyama, Elizabeth Winkler, Meredith Donahue, Sarah Ginther, Tellie Stamaris, Metamia Ciampricotti, Lucia Speroni, Brian D. Lehmann, Ben H. Park, Jennifer B. Gordetsky, Paula J. Hurley
Background
Risk stratification of prostate cancer is critical for guiding treatment decisions. One of the strongest prognostic indicators of clinical outcome is Grade Group (GG). However, intermediate risk prostate cancer pathology, comprising favorable (GG2) and unfavorable (GG3) disease, represents a heterogenous group of patients with varied outcomes, making risk stratification and treatment discussions particularly challenging. Incorporation of cribriform morphology in prostate cancer pathology improves patient stratification due to its important prognostic and therapeutic implications. Cribriform morphology, observed in invasive cribriform prostate adenocarcinoma (ICC) and intraductal carcinoma of the prostate (IDC), is an aggressive histological subtype that is associated with poor outcomes including higher risks of biochemical recurrence, metastasis, and mortality. A deeper understanding of the molecular mechanisms underlying the aggressive behavior of cribriform tumors is necessary to enhance clinical utility and to inform management.
Methods
To identify germline and somatic alterations associated with cribriform architecture in intermediate grade prostate cancer, we compared GG2 and GG3 tumors with cribriform morphology to tumors exhibiting other Gleason pattern 4 morphologic patterns (fused, poorly-formed, and glomeruloid). Clinical outcomes, germline variants, somatic genomic alterations, and transcriptomic profiles were evaluated and integrated to identify molecular subtypes.
Results
In intermediate grade prostate cancer, cribriform morphology was an adverse prognostic feature, associated with higher CAPRA-S scores and a shorter time to progression compared to non-cribriform Gleason pattern 4 morphologies. Pathogenic germline variants were uncommon in GG2/GG3 tumors irrespective of morphology. In contrast, cribriform tumors showed significant enrichment of genomic and transcriptional alterations involving DNA damage response and repair (DDR), the PTEN-PI3K axis, and WNT signaling. Non-cribriform cases were instead enriched for KDM6A alterations. Transcriptomic profiling further linked cribriform morphology with increased MYC signaling, estrogen-related programs, metabolic activity, and the PAM50 luminal B (LumB) subtype. Integrative genomic-transcriptomic analysis delineated five distinct molecular subtypes of cribriform prostate cancer: DDR, Inflammatory, PI3K, WNTMUT/SPOPMUT, and WNTLigand, whereas non-cribriform tumors were primarily stratified by ETS status.
Conclusions
Cribriform histology defines a clinically aggressive subset of intermediate grade prostate cancer characterized by distinct genomic alterations and molecular subtypes. The identification of molecularly defined cribriform subtypes highlights potential biological drivers and therapeutic targets, supporting the integration of cribriform morphology and its underlying molecular correlates into contemporary risk stratification and treatment decision-making.
Related publications